Navigation Links
Oncos Therapeutics Initiates Phase I Clinical Study of CGTG-102, an Oncolytic Adenovirus for the Treatment of Solid Tumor Cancers
Date:5/29/2012

HELSINKI, Finland, May 29, 2012 /PRNewswire/ --

Oncos Therapeutics today announced the successful initiation of its Phase I clinical study of CGTG-102, an oncolytic adenovirus suggested as a potential new treatment for many types of solid tumors. The first patients have already completed the safety assessment part of the study.

"We are proud to be the first clinic in Northern Europe to start a clinical study with oncolytic viruses," comments the Principal Investigator of the study, Chief Physician of Docrates Hospital, Dr. Timo Joensuu. "We believe that oncolytic adenoviruses, a generally well tolerated therapy, will have an important role in the future of cancer treatments."

"In our earlier experimental use the treatment has appeared to be safe for cancer patients. We really look forward to establishing the same safety in a clinical study with a more advanced dosing schedule. We believe the schedule used in the trial will also eventually contribute to the efficacy of the therapy," adds Helsinki University's Research Professor Akseli Hemminki, co-inventor of CGTG-102 and co-founder of Oncos Therapeutics.

The patient data cumulated over the past 5 years have contributed significantly to the design of the entire clinical development program of the company. "In addition to existing clinical safety data, which is unique to this stage of development, we also have a wealth of supportive data to guide the selection of target tumor types, optimal treatment administration, and other essential elements including clues regarding mechanism of action and possible biomarkers. We are very excited about the design of our entire development program driven by clinical data," summarizes Chief Medical Officer and Head of Research of Oncos Therapeutics, Mikael von Euler.

About Oncos Therapeutics

Oncos Therapeutics, based in Helsinki, Finland, develops novel cancer therapies based on its next generation oncolytic viruses. Its clinical development program of the lead virus CGTG-102 is based on clinical experience from an experimental treatment program with ten different oncolytic viruses, and is planned to expand into several countries in the near future. For more information about Oncos visit http://www.oncos.com.


'/>"/>
SOURCE Oncos Therapeutics Ltd
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. OncoSec Medical Licenses Non-DNA Vaccine Tumor Therapy Technology from Inovio Pharmaceuticals
2. Inovio Pharmaceuticals Licenses Non-DNA Vaccine Tumor Therapy Technology to OncoSec Medical
3. OncoSec Medical to Present at ROTH 23rd Annual Growth Stock Conference
4. OncoSec Medical Closes $1.1M Financing
5. OncoSec Medical Closes Purchase and License Agreement for Tumor Therapy Technology with Inovio Pharmaceuticals
6. OncoSec Medical Announces the Appointment of Dr. Anthony E. Maida, III, to Its Board of Directors
7. OncoSec Medical Appoints Engineering Leader
8. OncoSec Medical to Present at Industry and Investor Conferences
9. OncoSec Medical to Attend 6th Annual Fire, Ice and Beyond: The Future of Ablation Therapies Conference
10. OncoSec Announces Positive Results from Head & Neck and Breast Cancer Trials
11. Update: OncoSec Announces Positive Results From Head & Neck and Breast Cancer Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2020)... ... May 26, 2020 , ... Rize ... dicentra , seeking to provide them with revolutionary clinical trial solutions. , Through ... platform, an end-to-end solution that enables onboarding, scheduling, and remote data capture - ...
(Date:5/21/2020)... ... May 21, 2020 , ... ... in mid-March 2020 to deliver thousands of critical Personal Protection Equipment (PPE) devices ... their usual aerospace production work, the three companies teamed together to start production ...
(Date:5/21/2020)... ... 2020 , ... MedTech Breakthrough , an independent market ... health and medical technology market, today announced that Hospital IQ , the ... of its “Health Administration Innovation Award” in the fourth annual MedTech Breakthrough Awards ...
Breaking Medicine Technology:
(Date:5/28/2020)... (PRWEB) , ... May 28, 2020 , ... ... an important new 7th Donor Shield protection. Donors can now be reimbursed for ... Donor Shield program. The other six Donor Shield protections include lost wage reimbursement ...
(Date:5/27/2020)... ... May 27, 2020 , ... ... Dr. Gerald Pollack, University of Washington Professor of Bioengineering, Founder & Editor ... Solid, Liquid & Vapor ( https://www.amazon.com/Fourth-Phase-Water-Beyond-Liquid-ebook/dp/B00N2ASKF2 ) , https://www.voiceamerica.com/episode/123059/the-fourth-phase-of-water ...
(Date:5/26/2020)... ... May 26, 2020 , ... As much of ... the United States are joining forces to start a country-wide movement of physical ... to save lives. #FitForTheFrontLine is a national fitness challenge beginning Tuesday, May 26 ...
(Date:5/21/2020)... ... May 21, 2020 , ... Fujirebio Diagnostics, Inc., a ... assays, announced today that Cigna has added ROMA® (Risk of Ovarian Malignancy Algorithm) ... company dedicated to improving the health, well-being, and peace of mind of the ...
(Date:5/21/2020)... , ... May 21, 2020 , ... ESO , ... hospitals, today announced the findings of its 2020 ESO Fire Service Index . ... EMS calls versus fire-related calls, first apparatus turnout time and travel time, the most ...
Breaking Medicine News(10 mins):